DeGT is as effective as RGT in treating various MS-related factors, including energy intake, fat mass, hypertension, serum L/A ratio, serum corticosterone and 11βHSD1 in adipose tissue, TNF-α in adipose tissue, adipocyte hypertrophy, enlargement of Bowman’s space area and glomerular atrophy. This evidence concerns the gene TNF and myeloid sarcoma.